CN104000827A - 一种含有活性成分盐酸纳美芬的药物组合物 - Google Patents
一种含有活性成分盐酸纳美芬的药物组合物 Download PDFInfo
- Publication number
- CN104000827A CN104000827A CN201410256826.4A CN201410256826A CN104000827A CN 104000827 A CN104000827 A CN 104000827A CN 201410256826 A CN201410256826 A CN 201410256826A CN 104000827 A CN104000827 A CN 104000827A
- Authority
- CN
- China
- Prior art keywords
- nalmefene
- pharmaceutical composition
- injection
- hydrochloride
- weight portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- GYWMRGWFQPSQLK-OPHZJPRHSA-N (4r,4as,7as,12bs)-3-(cyclopropylmethyl)-7-methylidene-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol;hydron;chloride Chemical compound Cl.N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 GYWMRGWFQPSQLK-OPHZJPRHSA-N 0.000 title claims abstract description 67
- 229960000677 nalmefene hydrochloride Drugs 0.000 title claims abstract description 67
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 35
- 238000002347 injection Methods 0.000 claims abstract description 35
- 239000007924 injection Substances 0.000 claims abstract description 35
- 229960005297 nalmefene Drugs 0.000 claims abstract description 35
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 40
- 238000003756 stirring Methods 0.000 claims description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
- 239000008215 water for injection Substances 0.000 claims description 39
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 claims description 34
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 34
- 239000007788 liquid Substances 0.000 claims description 32
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 31
- 229960003511 macrogol Drugs 0.000 claims description 31
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 25
- 229910052799 carbon Inorganic materials 0.000 claims description 25
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 21
- 239000004480 active ingredient Substances 0.000 claims description 19
- 238000001914 filtration Methods 0.000 claims description 17
- 239000011780 sodium chloride Substances 0.000 claims description 17
- 238000007689 inspection Methods 0.000 claims description 14
- 239000012982 microporous membrane Substances 0.000 claims description 14
- 230000001954 sterilising effect Effects 0.000 claims description 14
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 3
- 229960005250 naloxone hydrochloride Drugs 0.000 abstract description 12
- RGPDIGOSVORSAK-STHHAXOLSA-N naloxone hydrochloride Chemical compound Cl.O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C RGPDIGOSVORSAK-STHHAXOLSA-N 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 229960002989 glutamic acid Drugs 0.000 abstract 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 18
- 238000012360 testing method Methods 0.000 description 16
- 239000004220 glutamic acid Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 239000013558 reference substance Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 238000009512 pharmaceutical packaging Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000018526 Narcotic-Related disease Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 231100000570 acute poisoning Toxicity 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 102000051367 mu Opioid Receptors Human genes 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 239000003401 opiate antagonist Substances 0.000 description 1
- 201000005040 opiate dependence Diseases 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- AHYACRDKWFXYLR-UHFFFAOYSA-M potassium N,N-diethylethanamine dihydrogen phosphate methanol Chemical compound [K+].OC.OP(O)([O-])=O.CCN(CC)CC AHYACRDKWFXYLR-UHFFFAOYSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 108020001612 μ-opioid receptors Proteins 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410256826.4A CN104000827B (zh) | 2014-06-11 | 2014-06-11 | 一种含有活性成分盐酸纳美芬的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410256826.4A CN104000827B (zh) | 2014-06-11 | 2014-06-11 | 一种含有活性成分盐酸纳美芬的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104000827A true CN104000827A (zh) | 2014-08-27 |
CN104000827B CN104000827B (zh) | 2017-11-17 |
Family
ID=51361917
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410256826.4A Active CN104000827B (zh) | 2014-06-11 | 2014-06-11 | 一种含有活性成分盐酸纳美芬的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104000827B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106727293A (zh) * | 2016-12-12 | 2017-05-31 | 河南润弘制药股份有限公司 | 一种盐酸纳美芬注射液及其制备方法 |
CN109200017A (zh) * | 2018-11-22 | 2019-01-15 | 辽宁海思科制药有限公司 | 一种盐酸纳美芬注射液药物组合物及其制备方法 |
CN113493468A (zh) * | 2020-03-18 | 2021-10-12 | 四川海思科制药有限公司 | 一种新的纳美芬二聚体及其制备方法和用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101406474A (zh) * | 2008-02-28 | 2009-04-15 | 云南绿野生物医药有限公司 | 纳美芬注射液及其制备方法 |
CN101732313A (zh) * | 2008-11-25 | 2010-06-16 | 北京四环制药有限公司 | 一种盐酸纳洛酮与聚乙二醇的药物组合物及其制备方法 |
-
2014
- 2014-06-11 CN CN201410256826.4A patent/CN104000827B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101406474A (zh) * | 2008-02-28 | 2009-04-15 | 云南绿野生物医药有限公司 | 纳美芬注射液及其制备方法 |
CN101732313A (zh) * | 2008-11-25 | 2010-06-16 | 北京四环制药有限公司 | 一种盐酸纳洛酮与聚乙二醇的药物组合物及其制备方法 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106727293A (zh) * | 2016-12-12 | 2017-05-31 | 河南润弘制药股份有限公司 | 一种盐酸纳美芬注射液及其制备方法 |
CN109200017A (zh) * | 2018-11-22 | 2019-01-15 | 辽宁海思科制药有限公司 | 一种盐酸纳美芬注射液药物组合物及其制备方法 |
CN109200017B (zh) * | 2018-11-22 | 2021-03-02 | 辽宁海思科制药有限公司 | 一种盐酸纳美芬注射液药物组合物及其制备方法 |
CN113493468A (zh) * | 2020-03-18 | 2021-10-12 | 四川海思科制药有限公司 | 一种新的纳美芬二聚体及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN104000827B (zh) | 2017-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100536848C (zh) | 稳定的盐酸纳美芬注射液及其制备方法 | |
CN104000827A (zh) | 一种含有活性成分盐酸纳美芬的药物组合物 | |
CN102552119A (zh) | 一种盐酸氨溴索葡萄糖注射液及其制备方法 | |
CN101756915B (zh) | 盐酸替罗非班冻干粉针注射剂及制备方法 | |
CN101406474A (zh) | 纳美芬注射液及其制备方法 | |
CN109662950A (zh) | 一种含有盐酸达泊西汀的药物组合物 | |
CN103463614B (zh) | 一种阿加曲班注射液及其制备方法 | |
CN102846575A (zh) | 硝苯地平缓释片及其制备方法 | |
CN102266343A (zh) | 供注射用盐酸法舒地尔药物组合物 | |
CN100455286C (zh) | 帕洛诺司琼注射液及其制备方法 | |
CN102600072B (zh) | 盐酸替罗非班注射液及其制备方法 | |
CN101732313B (zh) | 一种盐酸纳洛酮与聚乙二醇的药物组合物及其制备方法 | |
CN104771356A (zh) | 一种拉科酰胺注射液及其制备方法 | |
CN104997728A (zh) | 一种盐酸纳美芬注射液药物组合物及其制备方法 | |
CN109381431B (zh) | 石杉碱甲缓释微丸及其制备方法 | |
CN101428020A (zh) | 一种苦参素冻干粉制剂及其制备和检测方法 | |
CN103655607B (zh) | 一种含有奥美拉唑的药物组合物 | |
CN100374143C (zh) | 供静脉注射用天麻素冻干粉针剂及其制备工艺 | |
CN104971040B (zh) | 一种甲磺酸非诺多泮注射液及其制备方法 | |
CN107744501A (zh) | 一种汉防己碱的注射用药物组合物 | |
CN103536527B (zh) | 氢溴酸右美沙芬注射液及其制备方法 | |
CN102423295B (zh) | 一种含有长春西汀的小容量注射液组合物及其制备方法 | |
CN107823130A (zh) | 一种汉防己碱注射制剂药物组合物的制备方法 | |
CN103040738B (zh) | 一种含有盐酸法舒地尔化合物的药物组合物 | |
CN107913245A (zh) | 一种左乙拉西坦氯化钠注射液的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: TIBET YIMING XIYA BIOPHARMACEUTICAL TECHNOLOGY CO. Free format text: FORMER OWNER: BEIJING YIMING KANGYUAN PHARMACEUTICAL TECHNOLOGY CO., LTD. Effective date: 20141009 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100098 HAIDIAN, BEIJING TO: 850000 LHASA, TIBET AUTONOMOUS REGION |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20141009 Address after: Lin Qionggang road Lhasa 850000 Tibet autonomous region economic and Technological Development Zone Applicant after: Tibet Yiming Xiya Biological Medical Technology Co., Ltd. Address before: 100098 Beijing city Haidian District No. 48 Zhichun Road Yingdu building block C 4-15A Applicant before: Beijing Yiming Kangyuan Pharmaceutical Technology Co., Ltd. |
|
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: Lin Qionggang road Lhasa 850000 Tibet autonomous region economic and Technological Development Zone Applicant after: XIZANG YIMING XIYA PHARMACEUTICAL TECHNOLOGY CO., LTD. Address before: Lin Qionggang road Lhasa 850000 Tibet autonomous region economic and Technological Development Zone Applicant before: Tibet Yiming Xiya Biological Medical Technology Co., Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: TIBET YIMING XIYA BIOPHARMACEUTICAL TECHNOLOGY CO., LTD. TO: XIZANG YIMING XIYA PHARMACEUTICAL TECHNOLOGY CO., LTD. |
|
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: Lin Qionggang road Lhasa 850000 Tibet autonomous region economic and Technological Development Zone No. 6 Applicant after: XIZANG YIMING XIYA PHARMACEUTICAL TECHNOLOGY CO., LTD. Address before: Lin Qionggang road 850000 Tibet Lhasa economic and Technological Development Zone Applicant before: XIZANG YIMING XIYA PHARMACEUTICAL TECHNOLOGY CO., LTD. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |